A review of techniques oncology nurses can use to help themselves cope with their feelings as they navigate through the effects of the COVID-19 pandemic on their practice, their patients, and themselves.
It may be important to sequence ETV6in patients with inherited thrombocytopenia or malignancy and to schedule regular follow-ups to check for secondary cancers.
In this phase I clinical trial, 2 different cohorts of patients with acute GVHD received subcutaneous injections of uhCG along with standard-of-care treatment.
Families affected by the emotional burden of childhood cancer often face significant financial difficulty due treatment expenses and time away from work.
Although pediatric patients with malignancy-associated HLH may have low mortality rates, they may subsequently die from underlying conditions from the malignant disease.
After defining mortality-related parameters in HLH, investigators noted that mortality rates were still high for patients with primary immunodeficiency.
Researchers assessed data from patients with CAD with the aim of providing information on real-world, long-term outcomes of previously studied therapies.
The FDA has approved a phase 1/2a study evaluating the use of umbilical cord mesenchymal stem cells for the treatment of patients with severe cases of COVID-19.
ILROG has issued guidelines on alternative radiation treatment methods to combat limited treatment resources for cancer patients during the COVID-19 pandemic.
Investigators recommend that clinicians monitor WBC, lymphocyte, and platelet counts, as well as IL-6 and serum ferritin, in hospitalized COVID-19 patients with respiratory distress.
Inclusion of nurses in the development of health care programs relating to prevention and management of COVID-19 infection was a key element of the ISNCC position statement.
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
The use of telemedicine has been surging since the onset of COVID-19, with millions of Americans now using this medium for connecting with their clinicians.
Pyruvate kinase deficiency in erythrocytes can lead to hemolysis, which may cause significant hematologic comorbidities such as anemia, thrombosis, and iron overload.
The FDA has launched a new webpage with information for recovered individuals who were infected with coronavirus disease 2019 (COVID-19) on where they can go to donate plasma to aid in the treatment of severely ill patients.
Most cancer care is delivered at community oncology centers, but research regarding the barriers to clinical trial enrollment in this setting has been limited.
Although allogeneic HCT is associated with increased risk for keratinocyte carcinoma, the magnitude of risk linked to certain patient characteristics is still unknown.
Hydroxychloroquine is a less-toxic metabolite of the antimalarial drug chloroquine and is used as an immunomodulator for the treatment of autoimmune diseases.
Patient interviews revealed that most readmissions occur because patients are unsure of the availability and suitability of their care resources at home and in the outpatient setting.
The American Board of Internal Medicine (ABIM) announced that certified physicians who have a Maintenance of Certification (MOC) requirement due in 2020 will now have until the end of 2021 to complete it.
Survivors of childhood hematologic malignancies with poorly reported patient outcomes may have more chronic health conditions, regardless of treatment method.
There was evidence that sensitivity may be low in early stage disease (18% for stage I in all cancer types), vs 43%, 81%, and 93% in stages II, III, and IV, respectively.
The aim of this qualitative study was to explore the perspectives of clinical trial “stakeholders” regarding enrollment of minorities in cancer clinical trials.
For patients with porphyria cutanea tarda, reduced health-related quality of life may be associated with lack of treatment initiation and more symptoms.
Patients with cancer aged 65 and older are likely to be taking 5 or more medications before treatment with IV chemotherapy, which can complicate posttreatment care.
While 85% of nonatopic donors matched with nonatopic recipients remained nonatopic, 61% of atopic donors matched with atopic recipients became nonatopic after AHCT.
